Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics

Clinical effects of CYP2D6 phenoconversion in patients with psychosis

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

The Use of Oral Suspension and Rationally Prescribing Alternatives May Be Supplemental to the Implementation of Clopidogrel New Algorithm Comprising CYP2C19 Pharmacogenetics and Drug Interactions

The surgical atrial fibrillation ablation with concomitant coronary artery bypass grafting on the testing grounds of cost and 1-year mortality.

Clinical applications of CYP genotyping in psychiatry

Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study

The Cytochrome P450 2D6 (CYP2D6) Enzyme Polymorphism: Screening Costs and Influence on Clinical Outcomes in Psychiatry

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis

Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection

Unidentified CYP2D6 genotype does not affect pharmacological treatment for patients with first episode psychosis

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank

Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

Phenotype–Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

CYP2C19 genotype has prognostic value in specific populations following coronary stenting

The Influence of CYP2C19 Polymorphisms on Voriconazole Trough Concentrations: Systematic Review and Meta-Analysis.

Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study

Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis